CIRSE 2023

Profound Medical Corp and Philips team up to fight prostate cancer care

Profound Medical Corp. and Philips have signed a sales and marketing agreement to advance the commercial launch of Profound’s TULSA-PRO™, a minimally invasive system to ablate targeted prostate tissue. This technique has the potential to save sensitive anatomical structures around the prostate to promote better quality of life for the patient.

TULSA (Transurethral Ultrasound Ablation) technology combines real-time Magnetic Resonance (MR) imaging with transurethral therapeutic, robotically-driven ultrasound and closed-loop thermal feedback control. It will be combined with Philips MR-HIFU (high intensity focused ultrasound) to provide a highly precise treatment tailored to patient-specific anatomy and pathology.

Performed in an interventional MRI setting, it is the natural next step from MR imaging based diagnosis and MR guided prostate biopsy to therapy delivery. Aiming at comparable clinical outcomes as established therapy regimes, while minimizing treatment related morbidity and preserving quality of life of prostate cancer patients, TULSA-PRO MR guided high intensity ultrasound prostate cancer therapy has the potential to attract large numbers of patients to our customers’ institutions.

Learn more 

You are about to visit a Philips global content page


You are about to visit a Philips global content page


Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.

Jūs ieejat Latvijas Philips Healthcare tīmekļa vietnē.
Please select the checkbox

Tīmekļa vietne ir paredzēta tikai personām, kuras izmanto medicīniskās ierīces kā profesionāļi, tostarp personām, kas praktizē medicīnas profesijās, personām, kas darbojas veselības aprūpes iestāžu labā vai organizācijām, kas tirgo medicīnas ierīces kā profesionāļi.

Vai esat persona, kas atbilst iepriekš minētajiem kritērijiem?